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Chapter 1: Introduction 




and	 feet.	 It	 has	 an	 estimated	 incidence	 of	 1%.1	 A	 combination	 of	






1.2 Increased Risk of Atherosclerosis among subjects with RA 
	
Patients	 with	 RA	 carry	 an	 increased	 risk	 of	 cardiovascular	 disease	 (CVD)	
which	is	comparable	to	that	of	diabetes.2	Patients	with	RA	are	twice	as	likely	
to	 die	 from	 sudden	 cardiac	 death	 as	 their	 disease	 free	 counterparts	 and	
myocardial	 infarction	 remains	 the	 leading	 cause	 of	 death	 among	 subjects	
with	RA.3	
The	 increased	 risk	 of	 atherosclerosis	 among	 RA	 subjects	 remains	
incompletely	 understood.	 Traditional	 Framingham	 risk	 factors	 such	 as	
dyslipidaemia,	hypertension	and	smoking	are	increased	among	patients	with	
RA.4–6	Systemic	inflammation	promotes	a	pro-atherogenic	lipid	profile	in	RA	
resulting	 in	high	 levels	of	LDL	cholesterol	and	 low	 levels	of	HDL,	which	 in	




joint	 destruction	 and	 cardiovascular	 morbidity	 and	 mortality.	 Individuals	
who	possess	the	shared	epitope	and	who	smoke	have	an	 increased	risk	of	
developing	 seropositive	 RA	 with	 a	 tendency	 towards	 aggressive,	 erosive	
disease.7	 There	 is	 also	 data	 to	 suggest	 that	 individuals	 who	 possess	 the	
shared	epitope	are	at	 increased	risk	of	developing	atherosclerotic	plaques	




to	 the	 overall	 increased	 CVD	 risk,	 there	 is	 evidence	 to	 suggest	 that	 other	
pathological	mechanisms	may	also	play	a	role.	
Cadaver	 studies	 have	 shown	 that	 the	 atherosclerotic	 plaque	 burden	 in	
subjects	with	RA	vs.	controls	 is	similar,	but	that	subjects	with	RA	carry	an	
increased	amount	of	unstable	plaque.	This	would	suggest	that	subjects	with	
RA	 are	 at	 an	 increased	 risk	 of	 plaque	 instability,	 likely	 driven	 by	 pro-
inflammatory	mechanisms	that	are	common	to	both	RA	and	atherosclerosis.	
	












debris	 is	 covered	 by	 a	 fibrous	 cap	 consisting	 of	 smooth	muscle	 cells	 and	
collagen	 rich	matrix.	 	 It	 is	 the	 breakdown	of	 this	 cap	 that	 leads	 to	 plaque	
rupture,	 extrusion	 of	 plaque	 contents	 and	 ultimately	 thrombosis	 or	
embolisation.13	
A	combination	of	dyslipidaemia	and	haemodynamic	‘shear	stress’	is	thought	
to	 form	 the	 initial	 insult	 that	 provokes	 the	 onset	 of	 plaque	 formation	 and	
progression.	 Excess	 LDL	 particles	 migrate	 through	 the	 vessel	 wall	 to	 the	
intima	 where	 they	 become	 oxidised	 leading	 to	 the	 formation	 of	
phospholipids	 which	 in	 turn	 activate	 endothelial	 cells,	 provoking	 the	
inflammatory	insult	necessary	for	plaque	formation.14,15	
Endothelial	cells,	once	activated,	engage	with	circulating	platelets	leading		to	





into	 the	 endothelial	 space	 where	 they	 are	 differentiated	 by	 macrophage	
colony-stimulating	 factor	 to	 become	 macrophages.17	 These	 macrophages	
ingest	 surrounding	 oxidised	 LDL,	 cell	 debris,	 and	 bacterial	 endotoxin	
evolving	into	a	lipid	laden	macrophage	or	foam	cell,	the	prototypical	cell	of	
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the	 atherosclerotic	 plaque.	 Macrophages	 and	 foam	 cells	 in	 turn	 become	
activated	by	 toll	 like	 receptors	 (TLRs)	on	 the	cell	 surface	 in	 response	 to	a	
variety	of	antigens	to	become	the	main	source	of	cytokine	production	within	
the	atheromatous	plaque.18	





cytokines	 leads	 to	 a	 pro-	 inflammatory	 cascade	 which	 promotes	
atherosclerosis	 and	 the	 production	 of	 other	 cytokines	 downstream	 e.g.	 c-
reactive	 protein	 (CRP)	 and	 interleukin-6	 	 (IL-6)	 which	 can	 be	 detected	
systemically.18	
Whilst	a	universal	association	between	patients	with	atherosclerosis	and	all	




subset	 of	 T	 cells	 appears	 to	 possess	 marked	 inflammatory	 and	 tissue	
damaging	 properties.	 They	 secrete	 an	 abundance	 of	 pro-inflammatory	
cytokines	which	in	turn	promotes	endothelial	 injury	and	are	thought	to	be	
key	 proponents	 of	 plaque	 rupture.19	 These	 findings	 suggest	 that	 an	




RA	 and	 atherosclerosis	 exist,	with	 both	 diseases	 sharing	 	 similar	 immune	
mechanisms.	These	shared	mechanisms	could	help	to	explain	the	increased	
CVD	risk	that	is	evident	in	RA.	
For	 the	purpose	of	 this	 thesis	 I	decided	 to	explore	 this	concept	 further	by	
focusing	 on	 two	 separate	 immune	 mechanisms	 common	 to	 both	 RA	 and	





1.4 Fractalkine and CX3CR1- Structure and Function 
	
CX3CR1	 is	 a	 specific	 chemokine	 receptor	 for	 the	 chemokine,	 fractalkine	
(FKN).	 FKN	 belongs	 to	 a	 family	 of	 small	 8-10	 kDa	 proteins	 known	 as	
chemokines	 which	 function	 mainly	 as	 chemoattractant	 cytokines.21	




family	 and	 is	 also	 named	 CX3CL1	 (CX3C	 ligand	 1).	 It	 is	 the	 largest	 of	 the	
chemokines	consisting	of	373	amino	acids	and	can	exist	in	both	soluble	and	




be	 cleaved	 by	 proteolysis	 to	 yield	 a	 soluble	 form	 of	 FKN.25,26	 FKN	 may	
therefore	 function	 as	 an	 adhesion	molecule	when	 in	 its	membrane	bound	
form	and	as	a	chemoattractant	molecule	when	in	its	soluble	form.		
	








It	 differs	 from	 the	 other	 chemokines	 in	 that	 it	 demonstrates	 remarkable	
specificity	 for	 binding	 to	 its	 receptor,	 CX3CR1	 and	 is	 able	 to	 bind	 to	 its	




It	 also	 possesses	 powerful	 chemoattractant	 properties	 and	 has	 been	




In	 addition	 to	 its	 cell	 adhesion	 and	 chemoattractant	 properties,	 the	
interaction	 of	 FKN/	 CX3CR1	 facilitates	 a	 number	 of	 functions	 that	 are	
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important	 in	 the	pathogenesis	of	RA.	These	 include:	 the	 transmigration	of	
inflammatory	cells	to	the	synovium,	neoangiogenesis	and	the	upregulation	of	
osteoclasts	 and	 MMPs	 which	 in	 turn	 are	 important	 mediators	 of	 joint	
destruction.28,30–32	
	
1.5 FKN/ CX3CR1 – Role in RA 
	
FKN	is	a	potent	chemoattractant	molecule	that	facilitates	the	transmigration	
of	 inflammatory	 cells	 through	 the	 blood	 vessel	 wall	 into	 the	 rheumatoid	






on	 the	 various	 cells	making	 up	 the	 inflammatory	 infiltrate	 in	RA	 are	 now	
discussed	separately.	
	
T Cells  
	
T	 cells	 and	 macrophages	 predominate	 the	 inflammatory	 infiltrate	 that	 is	
present	in	RA.33–35	In	peripheral	blood	taken	from	patients	with	RA,	CX3CR1	
expression	 on	 CD4+	 and	 CD8+	 T	 cells	 is	 increased	 when	 compared	 with	






Interestingly	 senescent	 CD4+	 T	 cells	 which	 lack	 CD28-	 are	 expanded	 in	
patients	with	RA,	also	aberrantly	express	CX3CR1.37	These	cells	overexpress	
INF-Y,	 are	 resistant	 to	 apoptosis	 and	 show	 increased	 cytolytic	 activity.	
Conditions	for	these	cells	to	enter	the	cell	cycle	are	enhanced	in	the	presence	
of	FKN.38	Therefore	the	FKN/CX3CR1	axis	not	only	augments	the	cytotoxic	






CX3CR1	 is	 highly	 expressed	 among	 macrophages	 and	 monocytes	 in	
rheumatoid	 synovium.	 In	 particular,	 a	 subtype	 of	monocytes	 that	 express	
both	CD14	and	CD16	 (CD14+CD16+)	are	 increased	 in	both	 the	serum	and	
synovial	tissue	(ST)	of	patients	with	RA.34	These	monocytes	express	CX3CR1	
more	readily	than	‘conventional’	CD14++CD16-	monocytes	and	appear	to	be	











a	 major	 source	 of	 FKN.1	 They	 are	 resistant	 to	 apoptosis	 and	 secrete	
proinflammatory	 proteases	 and	 cytokines	 that	 contribute	 to	 joint	








The	 FKN/	 CX3CR1	 axis	 also	 plays	 a	 role	 in	 osteoclast	 differentiation	 and	














Angiogenesis,	 the	 growth	 and	 proliferation	 of	 new	 blood	 vessels	 is	 a	 key	
factor	in	the	pathogenesis	of	RA.	Pannus	formation	characterised	by	highly	
vascularised,	tumour	like	expansion	of	the	synovium	is	pathognomic	of	the	
disease.	 This	 new	 vessel	 formation	 facilitates	 the	 extravasation	 of	
inflammatory	 cells	 into	 the	 synovium.	 New	 vessel	 formation	 requires	 the	
sequential	processes	of:	endothelial	cell	migration,	proliferation,	elongation,	
orientation	 and	 differentiation	 resulting	 in	 lumen	 formation,	 basement-
membrane	re-formation	and	anastomosis	with	other	vessels	to	create	new	
vascular	networks.42	FKN	has	been	demonstrated	 to	 facilitate	 this	process	
and	 can	 induce	 the	 proliferation,	migration	 and	 tube	 formation	 of	 human	
umbilical	 vein	endothelial	 cells	 in	both	 in	vitro	and	 in	vivo	experiments.43	
Furthermore	 SF	 deplete	 of	 FKN	 shows	 substantially	 reduced	 angiogenic	
activity,	further	evidence	of	its	pro-angiogenic	properties.44	
	
These	examples	 therefore	 illustrate	 the	 importance	of	FKN/CX3CR1	 in	 the	









1.6 FKN/ CX3CR1- Role in Atherosclerosis 
	
The	effects	of	the	fractalkine/CX3CR1	signalling	pathway	on		atherosclerosis	
has	 been	 demonstrated	 in	 both	 human	 and	 animal	 studies.	 Wong	 et	 al.,	
showed	 that	 CX3CR1	was	 highly	 expressed	 among	 foam	 cells	 and	 smooth	
muscle	 cells	 of	 human	 atherosclerotic	 arteries	 but	 not	 healthy	 control	
arteries.45	 Combadiere	 and	Lesnick	were	 able	 to	 show	 independently	 that	
pro-atherogenic	ApoE-/-	mice	deficient	in	CX3CR1	were	less	likely	to	develop	
atherosclerotic	plaques	than	mice	able	to	express	CX3CR1.46,47	Both	(ApoE-/-,	
CX3CR1-/-)	 and	 (ApoE-/-,	 CX3CR1+/-)	 mice	 were	 able	 to	 demonstrate	 a	
resistance	to	developing	atherosclerosis	compared	to	mice	with	both	copies	
of	the	CX3CR1	gene	(ApoE-/-,	CX3CR1+/+).	Lesnick	et	al	were	able	to	further	
demonstrate	 that	 CX3CR1	 deficient	 mice	 had	 reduced	 recruitment	 of	
macrophages	to	the	vessel	wall.	More	recently	the	effects	of	pharmacological	
inhibition	of	CX3CR1	 in	Apo	E	 -/-	mice	have	been	demonstrated.	Apo	E-/-	
mice	 treated	 with	 a	 CX3CR1	 antagonist	 develop	 reduced	 levels	 of	
atherosclerosis	and	reduced	 levels	of	monocyte	recruitment.	These	results	






The	 first	 study	 presented	 is	 a	 genetic	 case	 control	 study,	 which	 tests	 for	
association	between	2	SNPs	(rs3732378	and	rs3732379)	located	within	the	
	 18	
coding	 sequence	 of	 CX3CR1.	 The	 SNPs	 have	 been	 previously	 shown	 to	 a	
protective	association	against	developing	atherosclerosis.	Given	the	similar	
pathogenic	mechanisms	 that	occur	 in	 relation	 to	CX3CR1	and	RA	and	also	
CX3CR1	 and	 atherosclerosis	 we	 hypothesized	 that	 a	 similar	 protective	
association	would	be	observed	between	these	2	SNPs	and	RA.	





1.7 Platelet Activation in RA 
	
The	 final	part	of	 this	 thesis	 focuses	on	the	role	of	platelets	and	the	role	of	
platelet	activation	in	RA.		Platelets	are	well	known	for	their	role	in	thrombosis	
and	 haemostasis,	 however	 until	 recently,	 their	 inflammatory	 potential	
remained	 less	 well	 explored.	 Platelet	 activation	 results	 in	 the	 release	 of	
biologically	active	microparticles	(MP)	which	can	promote	the	expression	of	
a	host	of	 inflammatory	cytokines.48	 In	 the	setting	of	 thrombosis,	enhanced	
platelet	 activity	 results	 in	 the	 release	 of	 α-granules	 containing	 adenosine	
diphosphate	 (ADP),	 serotonin,	 P-selectin,	 chemokines	 and	 cytokines.49	
Release	 of	 these	 pro-thrombotic	 substances	 ultimately	 culminates	 in	
activation	 of	 the	 platelet	 specific	 integrin	 αIIbβ3,	 enhanced	 platelet	




in	 vascular	 inflammation,	 atherosclerotic	 plaque	 instability	 and	 plaque	
rupture.50,51	Platelet	activation	has	also	been	shown	to	occur	in	RA	and	could	
potentially	 help	 to	 explain	 the	 increased	 cardiovascular	 disease	 risk	 that	
exists	among	these	patients.	
Platelet	activation	in	RA	is	a	relatively	new	concept.		It	was	first	described	by	
Boilard	 et	 al.,	 who	 showed	 that	 platelet	 MPs	 were	 present	 in	 abundance	
within	human	RA	synovial	fluid	(SF),	and	were	capable	of	inducing	cytokine	
release	 from	 synovial	 fibroblasts.52	 Using	 a	 K/BxN	 serum	 transfer	mouse	






1.8 Soluble GPVI- A Useful Biomarker of Platelet Activation 
	
GPVI	is	a	~64	kDa	transmembrane	glycoprotein	which	is	found	exclusively	
on	 platelets	 and	 acts	 as	 the	 predominant	 platelet	 receptor	 for	 collagen.	 It	
contains	2	extracellular	immunoglobulin	(Ig)-	like	domains,	a	mucin	domain,	
transmembrane	domain	and	a	cytoplasmic	tail	of	approximately	50	residues.	
Within	 the	 cytoplasmic	 tail	 portion	 of	 the	 dimerized	 Fcγ	 chain	 are	 2	
immunoreceptor-tyrosine	based	active	motifs	(ITAM)s.	Signal	transduction	
occurs	when	 ligand	engages	with	GPVI	resulting	 in	phosphorylation	of	 the	









Recently	 it	 was	 demonstrated	 by	 Habets	 et	 al.,	 that	 platelet	 activation	 is	
associated	with	the	presence	of	ACPA	and	that	blockade	of	the	low	affinity	
platelet	 IgG	 receptor,	 FcγRIIa	 in	 vitro,	 inhibited	 ACPA-mediated	 platelet	
activation.55	 FcγRIIa	was	 therefore	 identified	 as	 the	 ligand	 through	which	
ACPA-mediated	 platelet	 activation	 occurs.	 	 FcγRIIa	 signaling	 is	 known	 to	
occur	in	conjunction	with	GPVI	such	that	ligand	binding	to	FcγRIIa	results	in	
‘dual	signaling’	of	FcγRIIa	and	GPVI	pathways	and	shedding	of	GPVI.54	This	
mechanism	 is	 not	 unique	 to	 ACPA	 and	 has	 been	 demonstrated	 in	 other	
diseases	such	as	 immune	mediated	thrombocytopenia	(ITP)	 in	which	anti-
platelet	antibodies	derived	from	a	patient	with	ITP	were	able	to	activate	GPVI	
via	 FcγRIIa.56,57	 Similarly,	 circulating	 immune	 complexes	 derived	 from	
patients	 with	 systemic	 lupus	 erythematosis	 (SLE)	 have	 been	 shown	 to	
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Chapter 2: Association between a polymorphism in the 
fractalkine receptor, CX3CR1 and rheumatoid arthritis: a 
genetic case control study 
2.1 Background: Genetics of Rheumatoid Arthritis 
2.1.1 The Genetic Basis of RA 
	
The	exact	cause	of	RA	remains	unknown	however	it	is	believed	to	arise	from	
a	 complex	 interplay	 of	 environmental	 and	 genetic	 factors.	 A	 genetic	
predisposition	to	developing	RA	is	well	established.1	Familial	studies	have	
demonstrated	 that	 first	 degree	 relatives	 of	 patients	 with	 RA	 are	
approximately	twice	as	likely	to	develop	RA	when	compared	to	their	healthy	








2.1.2 SNPs and RA 
	
SNPs	are	areas	of	genetic	variability	that	occur	frequently	among	the	general	









Whilst	 many	 SNPs	 remain	 undiscovered,	 advances	 in	 genotyping	
technology,	together	with	the	completion	of	the	human	genome	project	have	
led	 to	 the	 identification	 of	 101	RA	 associated	 SNPs	 among	European	 and	
Asian	populations.5–7	
2.1.3 The MHC and HLA-DRB1 Locus 
	
The	discovery	of	association	between	the	(human	leukocyte	antigen)	HLA-
DRB1	 locus	 and	 RA	 in	 the	 1970s	 remains	 perhaps	 the	 most	 important	
discovery	in	our	modern	day	understanding	concerning	the	genetic	basis	of	
RA.	 Researchers	 examining	 mixed	 lymphocyte	 cultures	 noticed	 that	
lymphocytes	derived	from	different	individuals	with	RA	tended	to	express	
similar	 HLA	 genes	 within	 the	 major	 histocompatibility	 complex	 (MHC)	
region,	 the	 protein	 responsible	 for	 antigen	 presentation.8,9	 Multiple	 risk	
alleles	 for	 RA	 were	 subsequently	 identified	 at	 the	 HLA-DRB1	 locus.10	
Molecules	encoded	by	these	alleles	share	a	conserved	amino	acid	sequence	
arranged	around	the	antigen	binding	groove,	known	as	the	‘shared	epitope.		
The	 shared	 epitope	 has	 been	 to	 shown	 to	 be	 associated	 with	 anti-
citrullinated	peptide	antibody	(ACPA)	positive	and	to	a	much	lesser	extent	
ACPA	 negative	 RA	 accounting	 for	 18%	 and	 2.4%	 of	 RA	 heritability	
respectively.11	 This	 association	 has	 given	 rise	 to	 the	 ‘shared	 epitope	
	 30	
hypothesis’	which	describes	 the	 SE	 facilitating	 the	binding	 of	 the	MHC	 to	
citrullinated	peptides,	 thus	triggering	a	T	cell	response	and	breakdown	in	
immune	 tolerance	 that	 ultimately	 manifests	 with	 RA.10	 Whilst	 much	
evidence	supports	the	‘SE	hypothesis’	controversy	remains	due	to	a	failure	
to	 unequivocally	 identify	 an	 ‘arthritogenic	 peptide’	 and	 	 the	more	 recent	
discovery	that	ACPA	negative	RA	is	also	associated	with	the	SE.5	
2.1.4 Other Notable SNPs  
	





















first	 SNP	associated	with	RA	 to	be	 identified	outside	of	 the	HLA.14	Unlike	
many	 other	 SNPs,	 which	 are	 often	 associated	with	multiple	 autoimmune	
diseases,	 PADI4	 is	 specifically	 associated	 with	 RA.	 	 PADI4	 mediates	 the	
citrullination	of	peptides.14	The	RA	susceptibility	haplotype	has	been	shown	









with	 RA	 emphasising	 the	 importance	 of	 	 the	 Th17	 pathway	 in	 the	
pathogenesis	of	RA.18	
2.1.5 Combining Environmental and Genetic Factors 
	
Genetics	 alone	 do	 not	 fully	 explain	 the	 aetiology	 of	 RA.	 Environmental	
factors	 also	 make	 up	 a	 significant	 contribution.19	 Many	 of	 these	 factors	
remain	to	be	discovered.	Smoking	and	periodontal	disease	have	both	been	
established	as	independent	risk	factors	for	the	development	of	RA	and	both	
are	 associated	 with	 increased	 expression	 of	 ACPAs.20,21	 Porphyromana	
gingivalis,	 a	 causative	 bacterium	 of	 periodontal	 disease,	 expresses	 PAD	
(PPAD),	 which	 is	 capable	 	 of	 citullinating	 human	 peptides.21	 Similarly	
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smokers	 demonstrate	 increased	 expression	 of	 PADI4.22	 Smoking	 and	
periodontal	 disease	may	 therefore	 facilitate	 the	 production	 of	 ACPAs	 via	
human	PADI4	and	PPAD	respectively.	Chronic	exposure	to	ACPAs	may	then	
in	 turn,	 lead	 to	 a	 breakdown	 in	 immune	 tolerance	 perpetuating	 an	
autoimmune	inflammatory	response	that	characterizes	RA.19		
2.2 Genetic association studies 
	




(cases	 and	 controls)	 i.e.	 that	 the	 differences	 in	 genotype	 frequencies	
observed	will	relate	to	the	characteristic	or	outcome	measured.	
2.2.1 Alleles and Haplotypes 
	
SNPs	usually	give	rise	to	2	alleles,	which	are	alternative	forms	of	the	same	
gene.	 The	 frequencies	 at	which	 they	 occur	 among	 a	 given	population	 are	
termed	the	major	and	minor	allele	frequencies,	with	the	major	allele	being	
the	more	frequently	occurring	allele.	Up	to	10	million	SNPs	are	thought	to	









2.2.2 Recombination and Linkage Disequilibrium 
	
Rarely,	 alleles	 lying	within	 the	 same	haplotype	 can	become	separated	via	
meiotic	crossing	–over	in	cells	undergoing	meiosis.	This	process	is	known	as	








searching	 of	 the	 human	 genome	 for	 areas	 of	 genetic	 variation	 that	 have	
important	functional	consequences.		A	comparatively	small	number	of	well	
chosen	 ‘tag	 SNPs’	 allows	 one	 to	 predict	 the	 remainder	 of	 SNPs	 within	 a	
particular	region.	LD	therefore	allows	us	to	predict	a	vast	number	of	SNPs	
(estimate	 10	million)	 by	 genotyping	 a	much	 smaller	 number	 of	 tag	 SNPs	
(200,000	to	1,000,000).23,26	
2.2.3 Utilising LD in the study of human genetics 
	
This	 concept	 has	 been	 put	 to	 effective	 use	 by	 way	 of	 the	 International	
HapMap	Project.	This	is	a	multi-national	not-for-profit	collaborative	project	
that	has	utilised	the	concept	of	LD	to	create	a	‘haplotype	map’	of	the	human	
genome.	 The	 data	 derived	 from	 the	 project	 allows	 researchers	 to	 study	
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haplotype	associations	and		identify	markers	of	specific	diseases	which	have	
genetic	determinants,	 ultimately	providing	 an	 invaluable	 resource	 	which	
can	be	accessed	free	and	openly.23	








cohorts	 are	 combined	 with	 high-throughput	 genotyping	 technology	 to	
genotype	between	100,000	to	1000,000	SNPs	allowing	the	 investigator	 to	
capture	65-70%	of	common	variation	across	the	human	genome.	In	doing	so	




<	5	 x	10^8	are	needed	 in	order	 to	 report	 a	 true	association.7	As	 a	 result,	
GWAS	 usually	 necessitate	 worldwide	 large-scale	 collaboration	 between	
investigators	in	order	to	achieve	the	large	numbers	of	cases	and	controls	that	
must	be	recruited.		







identified	 based	 upon	 prior	 known	 function	 or	 genetic	 information.	 For	
example,	several	SNPs	associated	with	type	1	diabetes	have	also	been	shown	
to	be	associated	with	RA:	CTLA4,	AFF3	and	4q27.30–32	Similarly	a	SNP	of	the		




a	 known	 biological	 function	 of	 a	 protein	 encoded	 by	 a	 gene	 that	 has	
relevance	 to	 a	 particular	 disease	 clearly	 offers	 major	 advantages	 over	
another	gene	of	which	the	biological	 function	is	unknown.	This	concept	 is	
known	 as	 biological	 plausibility	 and	 adds	 weight	 behind	 the	 power	 of	 a	
particular	study	when	it	exists.	Similarly,	studies	demonstrating	functional	
outcomes	 associated	 with	 gene	 dysfunction	 in	 animals	 can	 guide	 similar	
testing	 of	 genes	 among	 humans.	 Previous	 association	 studies	 showing	
association	 are	 also	 of	 relevance	 and	 provide	 strong	 indicators	 that	 a	
particular	gene	has	an	aetiological	role.	Genome	wide	association	studies	can	
also	 provide	 indicators	 of	 potential	 candidate	 genes	 by	 pointing	 towards	
areas	 of	 high	 LD	 associated	 with	 a	 high	 probability	 of	 containing	 a	
susceptibility	gene.34	




design	 and	 implementation	 that	 can	 ultimately	 lead	 to	 erroneous	
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somewhat	 more	 difficult.	 Reasonable	 effort	 must	 be	 made	 to	 ensure	 the	









Adequate	 description	 of	 ethnicity	 and	 population	 origin	 of	 cases	 and	
controls	is	therefore	important.	If	stratification	is	thought	to	be	present	then	
the	 additional	 genotyping	 of	 unlinked	 markers	 can	 be	 used	 as	 way	 of	
reducing	 false	 positive	 results	 created	 by	 population	 stratification.	 If	





population	 stratification	 should	 be	 minimal	 in	 association	 studies	
originating	from	Ireland.	
 
Study size and power 
	























Multiple testing effect 
	
When	multiple	 testing	 of	 the	 same	population	 takes	 place	 the	 chances	 of	











2.3 Association between a polymorphism in the fractalkine receptor, 
CX3CR1 and rheumatoid arthritis 
For	 this	 study	 we	 chose	 2	 candidate	 SNPs	 (rs3732378	 and	 rs3732379)	
located	within	the	coding	sequence	of	CX3CR1	to	test	for	association	with	RA	
based	upon	previous	 known	association	with	 atherosclerosis.	 	 Both	 SNPs	
(rs3732378	 and	 rs3732379)	 are	 missense,	 conservative	 SNPs,	 located	
within	 the	 sixth	 and	 seventh	 transmembrane	 domains	 of	 CX3CR1	









7	 case	 control	 studies	 reported	 in	 the	 literature	 to	 date.	 A	 recent	 meta-
analysis	of	these	studies	found	the	I249M280	haplotype	to	be	significantly	
more	 common	 among	 healthy	 controls	 compared	 to	 individuals	 with	
atherosclerosis.40	This	has	led	some	authors	to	speculate	that	the	I249M280	
haplotype	 may	 confer	 a	 protective	 effect	 against	 the	 development	 of	
atherosclerosis.41	This	hypothesis	 is	 supported	by	 some	 in	vitro	evidence	




No	 association	 between	 rs3732378	 and	 rs3732379	 has	 previously	 been	
reported	with	RA.	 Given	 the	 similar	 pathogenic	mechanisms	 that	 exist	 in	























































lysed	 by	 incubation	 with	 a	 lysis	 buffer	 containing	 a	 choatropic	 salt	 and	
Proteinase	K.	Magnetic	Glass	Particles	(MGPs)	were	added	and	DNA	binded	








3. Proteinase	 K	was	 added	 to	 the	 samples	 resulting	 in	 digestion	 of	
proteins.	
4. DNA	 binded	 to	 the	 silica	 surfaces	 of	 the	 added	MGPs	 due	 to	 the	
chaotropic	 salt	 conditions,	 isopropanol	 and	 the	high	 ionic	 strength	of	 the	
lysis/binding	buffer.	








8. The	 purified	 DNA	was	 eluted	 from	 the	MGPs	 in	 the	wells	 of	 the	
elution	cartridge.	MGPs	were	retained	in	the	reaction	tip	and	discarded.	
	
Genotyping and Statistics 
	
All	genotyping	was	performed	blind	to	case	control	status	by	KBioscience.	
SPSS	 and	 PLINK	 were	 used	 for	 statistical	 analysis.	 Genotype	 and	 allelic	





was	 set	 at	 0.3	 (based	 on	 previous	 frequencies	 reported	 in	 a	 large	meta-




























vs.	 VV;	 OR:	 1.18	 (95%	 CI,	 1.18	 –	 1.36);	 P	 =	 0.017).	 	 There	 was	 a	 higher	
frequency	 of	 AA	 or	 AG	 carriers	 in	 the	 controls	 (53.6%)	 versus	 the	 cases	
(45.4%).	 	 There	 was	 a	 higher	 frequency	 of	 rs3732378	 A	 alleles	 in	 the	
controls	 (31.0%)	 versus	 cases	 (26.6%),	 however,	 this	was	 not	 significant	
(OR:	0.81,	(95%	CI,	0.65-1.00);	P	=	0.055).			
	
































OR 95%CI P 
rs3732378 V249I      
 II 31 40 1.18^ (1.18-1.36) 0.017 
 VI 142 205    
 VV 204 207    
rs3732379 T280M      
 MM 11 14 1.17* (0.87-1.57) 0.281 
 TM 107 141    










CX3CR1	 polymorphisms	 were	 first	 identified	 by	 a	 team	 of	 French	
investigators	studying	the	functional	outcomes	of	CX3CR1	SNPs		on	CX3CR1	
expression	 in	 patients	 with	 HIV.39	 	 (In	 HIV,	 CX3CR1	 functions	 as	 a	 co-
receptor	 for	 the	 virus).	 They	 found	 that	 individuals	 expressing	 the	




of	 FKN	binding	 sites	was	 also	 reduced.	 These	 findings	 led	 the	 authors	 to	
speculate	 that	 reduced	 CX3CR1	 expression	 and	 FKN	 binding	 could	




coronary	 artery	 disease	 among	 individuals	 heterozygous	 for	 the	 I249	
allele.41	Whilst	the	numbers	included	in	this	study	were	small	(151	cases	and	






a	 reduced	 risk	 of	 atherosclerosis	 among	 patients	 heterozygous	 for	 the	
I249M280	haplotype	under	a	dominant	genetic	model	(OR	0.6;	p=0.008).42	
Again,	 reduced	 FKN	 binding	 	 was	 demonstrated	 in	 vitro	 among	 PBMCs	
derived	form	patients	expressing	the	I249M280	haplotype.	
	
Whilst	 subsequent	 case	 control	 studies	 have	 been	 inconsistent,	 a	 meta-
analysis	which	 included	 2000	 coronary	 artery	 disease	 patients	 and	 2841	
controls	 	 also	 found	 the	 I249M280	 haplotype	 to	 be	 significantly	 more	
common	 among	 	 controls	 compared	 to	 subjects	 with	 coronary	 artery	
disease.42	
	
These	 findings	 have	 led	 some	 authors	 to	 speculate	 that	 the	 I249M280	
haplotype	 could	 confer	 a	 protective	 effect	 against	 the	 development	 of	













These	 studies	 therefore	 support	 the	 hypothesis	 that	 reduced	 or	 altered	




As	with	 atherosclerosis,	 FKN/CX3CR1	 is	 also	highly	 expressed	 in	RA	 (see	
Chapter	1).	 It	 is	 interesting	 therefore,	 that	we	 found	a	 similar	association	










This	 study	has	 a	 number	 of	 limitations.	 The	 control	 cohort	was	provided	
from	a	biobank	of	DNA	donated	by	post-menopausal	women	between	1996	
and	2005.	Although	RA	was	excluded	from	these	patients	at	the	time	of	DNA	
extraction,	 it	 is	 impossible	 to	 know	whether	 or	 not	 any	 of	 these	 patients	
	 49	
subsequently	went	on	to	develop	RA	(as	the	samples	were	anonymised).	The	





This	 study	 represents	 a	 case	 control	 study	performed	on	 a	much	 smaller	
scale	 compared	 to	 that	 of	 the	 larger	 (Genome	 wide	 association	 studies)	
GWAS	case	control	studies	that	are	more	commonly	reported	in	the	current	
literature.	Whilst	this	study	may	lack	the	statistical	power	derived	from	such	
larger	 studies,	 it	 is	 supported	 by	 functional	 studies	 previously	 reported	





Some	 experts	 now	 argue	 that	 these	 2	 subgroups	 represent	 genetically	
different	phenotypes	and	should	be	grouped	together	separately	to	ensure	
homogeneity	 of	 the	 case	 population	 being	 studied.2	 This	 suggestion	 	 is	
largely	based	on	what	was	once	considered	an	almost	exclusive	association	
between	the	HLA-DB1	shared	epitope	and	ACPA-positive	RA.	We	now	know	
however	 that	 ACPA-	 negative	 RA	 is	 also	 associated	 with	 the	 shared	




In	 summary	 we	 found	 an	 association	 between	 the	 SNP	 rs3732378	 and	
subjects	with	RA	with	the	variant	allele	being	more	common	among	controls	
than	subjects	with	RA.	There	is	some	evidence	to	suggest	that	this	SNP	may	
confer	 a	 protective	 effect	 by	means	 of	 altered	 FKN	 binding	 and	 reduced	
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Chapter 3: Co-localisation of CX3CR1 and CD16+ and 
CD14+ mononuclear cells in rheumatoid synovium 
3.1 Introduction 
	
As	 discussed	 in	 Chapter	 1,	 the	 FKN/CX3CR1	 axis	 serves	 as	 a	 powerful	
chemoattractant.	For	this	chapter	I	decided	to	explore	the	effects	of	FKN/	
CX3CR1	 on	 monocytes	 in	 human	 RA	 synovium	 further	 by	 means	 of	
immunohistochemistry.	 Human	 blood	 monocytes	 are	 a	 heterogenous	
population.	They	can	be	divided	into	3	different	subsets:	classical	(CD14++	
CD16-),	 intermediate	 (CD14++CD16+)	 and	 nonclassical	 (CD14+CD16++).1	





MHC	 class	 2	 antigens,	 ICAM-1	 and	 VLA	 4.1,3,4	 IL-10	 expression	 is	 low	 or	
absent	from	these	monocytes.	
CD16+	monocytes	are	expanded	in	patients	with	active	RA.5	










To	 examine	 the	 co-localisation	 of	 CX3CR1	 with	 CD	 16+	 and	 CD14+	









Control	 ST	 was	 obtained	 from	 patients	 undergoing	 knee	 replacement	
surgery	for	OA	at	St	Mary’s	Orthopaedic	Hospital,	Cork.	All	patients	provided	
written	informed	consent.	















3.3.5 Immunohistochemical staining 
	




Antibody	 Manufacturer	 Host	 Dilution	
CD14	 Novocrasta	 Mouse	IgG2a	 1/100	
CD16	 Novocrasta	 Mouse	IgG2a	 1/100	




After	 co-staining,	 samples	 were	 incubated	 at	 room	 temperature	 for	 65	





























3.3.6 Isotype controls 
	
In	 order	 to	 estimate	 the	 contribution	 of	 non-specific	 antibody	 binding,	
isotype	controls	were	employed	using	serum	from	an	unimmunized	animal	
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of	 the	 same	 species	 as	 the	 primary	 antibody	 (i.e.	 rabbit	 or	 mouse	 as	
appropriate).	
3.3.7 Slide Analysis 
	
Slides	 were	 analysed	 using	 a	 NIKON	 confocal	 microscope	 and	 EZ-CI	























CD16+	 cells	 were	 less	 populous	 than	 CD14+	 cells.	 	 90%	 of	 RA	 sections	
analysed	detected	cells	expressing	CD16		compared	to	33%	of	OA	sections.	
















































Paraffin-embedded	 synovial	 tissue	 samples	 from	 individuals	 with	 RA	
(Column	on	the	left)	and	OA	(Middle)	were	stained	with	specific	antibodies	





















Paraffin-embedded	 synovial	 tissue	 samples	 from	 individuals	 with	 RA	
(Column	 to	 the	 left)	 and	 OA	 (middle	 column)	were	 stained	with	 specific	
antibodies	for	CX3CR1,	CD16	or	the	appropriate	isotype	control	(Column	to	















CX3CR1	 were	 present	 in	 abundance	 within	 the	 lining	 and	 sublining	 of	
rheumatoid	synovium.	CD16+	mononuclear	cells	were	also	present	albeit	in	
fewer	numbers	and	were	also	found	to	express	CX3CR1.		




to	 the	 lining	 and	 sublining	 layer	 of	 rheumatoid	 synovium	and	 co-express	
CX3CR1.6	 This	 was	 a	 small	 study	 however,	 including	 ST	 from	 only	 3	 RA	




Our	 study	 corroborates	 Yano	 et	 als	 findings	 in	 a	 larger	 cohort	 of	 patient	
samples	and	also	compares	the	differential	distribution	of	CD14+	and	CD16+	
mononuclear	cells	between	rheumatoid	and	OA	synovium.	
FKN	 is	highly	 expressed	 in	RA	 in	both	membrane	 and	 soluble	 form.7	The	
concentration	of	FKN	in	RA	synovial	fluid	is	greater	than	that	of	serum	FKN,	
therefore	providing	a	chemokine	gradient	down	which	CX3CR1	expressing	





In	addition	 to	 facilitating	 the	 trafficking	of	monocytes,	FKN	has	also	been	
shown	to	induce	the	secretion	of	IL-1B	and	IL-6	from	isolated	whole	blood	













in	 RA	 ST	 represents	 monocytes	 of	 the	 CD14+	 CD16++	 subset.	 These	
monocytes	 have	 previously	 been	 demonstrated	 to	 be	 increased	 in	 the	
peripheral	blood	and	synovial	compartment	of	patients	with	RA.5	









migration	 of	 these	 CD16+	 ‘inflammatory’	monocytes	 in	 vitro,	highlighting	
importance	of	the	FKN/CX3CR1	pathway	in	inflammatory	conditions	such	
as	RA.12	
Interestingly	 CD14+	 monocytes	 present	 in	 OA	 synovium	 also	 expressed	
CX3CR1.	 It	 would	 therefore	 appear	 that	 FKN/	 CX3CR1	 functions	 as	 a	
chemoattractant	for	all	subclasses	of	monocytes.	The	differential	expression	
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Chapter 4: Soluble glycoprotein VI, a specific marker of 
platelet activation is increased in the plasma of subjects 
with seropositive rheumatoid arthritis. 
4.1 Introduction 
	












Anti-citrullinated	 protein	 antibodies	 (ACPA)	 have	 been	 shown	 to	 cause	
platelet	activation	 in	vitro,	 through	the	 low-affinity	 immunoglobulin	G	(IgG)	
receptor	(FcγRIIa)	on	platelets.	Platelet	activation	via	engagement	of	FcγRIIa	
results	in	proteolytic	cleavage	and	shedding	of	platelet	specific	glycoprotein	VI	










84	 patients	with	 RA	 (65	 seropositive	 and	 19	 seronegative)	were	 recruited	
prospectively	at	the	Mater	Misericordiae	University	Hospital	(MMUH)	Dublin	
from	 2012	 until	 2016.	 They	 satisfied	 both	 the	 1987	 American	 College	 of	





the	 research	 ethics	 committee	 of	 the	 MMUH	 and	 RCSI.	 The	 study	 was	
conducted	according	to	the	principles	expressed	in	the	Declaration	of	Helsinki.	
Demographic	 and	 clinical	 data	 were	 collected	 for	 all	 participants.	
Characteristics	of	seropositive	vs	seronegative	RA	are	presented	in	Table	1.	
	
Blood Sampling and Plasma Preparation 
	
Blood	was	collected	 into	vacutainers	containing	0.106	nM	sodium	citrate	as	































































	 Sero	+	RA	 Sero	-	RA	 P	value	
Total	Number	 65	 19	 	
Female,	n	(%)	 51	(78)	 16	(84)	 ns	
Male,	n	(%)	 14	(21)	 3	(15)	 ns	
Age,	yr	(median	[IQR])	 62	[54-71]	 48[38-64]	 0.01	
CRP,	mg/l	(median	[IQR])	 8	[4-15]	 6	[2-21]	 ns	
ESR,	mm/hr	(median	[IQR])	 21	[11-32]	 13	[7-38]	 ns	
Fibrinogen	g/l	(mean	+/-	SEM)	 3.33	+/-	1.12	 4.06+/-1.92	 ns	
Platelet	Count	x	109(mean	+/-	SEM)	 281+/-	98	 285	+/-	81	 ns	
DAS28-CRP	(Mean	+/-	SEM)	 3.83	+/-	1.49	 4.37	+/-	2.2	 ns	
RF	titre,	IU/mL	(median	[IQR])	 81	[20-271]	 2.3	[1.5-4.7]	 <0.0001	










inflammed	 joints	 where	 they	 transmigrate	 into	 the	 inflammed	 synovium	












seropositive	 RA	 patients	 were	 positive	 for	 both	 ACPA	 and	 RF	 antibodies	
therefore	 we	 were	 unable	 to	 distinguish	 whether	 the	 association	 bewteen	
sGPVI	 and	 seropositive	 RA	 was	 due	 to	 the	 presence	 of	 ACPA,	 RF	 or	 both.	
Although	platelets	lack	the	Fc-IgM	receptor,	RF	factor	can	exist	in	both	IgM	and	








sGPVI	 in	 our	 patients	 was	 due	 to	 Fc RIIa-mediated	 pathways	 and	 our	




that	 could	 have	 further	 defined	 the	 degree	 of	 platelet	 activity	 in	 patients	
recruited	to	the	study.20	However,	previous	studies	have	illustrated	significant	
correlation	between	plasma	sGPVI	and		soluble	P-selectin,	with	sGPVI	having	











reduce	 collagen-induced	 platelet	 activation	 ex-vivo.24	 Blocking	 ITAM	
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signalling	by	targeting	the	tyrosine	kinases	and	adaptor	proteins	downstream	
of	 FcγRIIa	 and	GPVI	may	also	be	 a	potential	 approach	 for	 treatment	of	RA.	
Inhibitors	 such	 as	 fostamatinib	 (against	 Syk),	 ibrutinib	 (Btk	 inhibitor)	 and	
afuresertib	(PI-3	kinase	 inhibitor)	all	 target	members	of	 the	ITAM	signaling	
pathway	and	may	have	utility	in	RA	therapy.25–27	Some	of	these	reagents	are	
already	 in	 trial	 for	 the	 treatment	of	 chronic	 lymphocytic	 leukemia,	RA,	 and	
asthma.28–30	 Further,	 the	 Syk	 inhibitor	 PRT318	 reduces	 HIT	 and	 immune	
complex–mediated	 thrombosis	 in	 mice	genetically	 engineered	 to	 express	
platelet	 Fc RIIa.31	It	 is	 currently	 unknown	what	 effect	 using	 such	 targeted	




A	 role	 for	platelets	during	 the	 earliest	 phases	of	RA	pathogenesis	has	been	
hypothesized	previously.12,13	Under	favourable	conditions,	enhanced	vascular	
permeabilty	 could	 facilitate	 the	 transmigration	 of	 platelets	 and	 auto-
antibodies	 into	 inflammed	 joints	 where	 platelets	 subsequently	 become	
activated,	amplifying	further	vascular	and	synovial	inflammation.	Supporting	
this	hypothesis	is	the	fact	that		periodontal	disease	has	also	been	associated	
with	 platelet	 activation.32,33	 The	 pathogen	 of	 this	 disease,	 Porphyromonas	
gingivalis	can	migrate	haematogenously	from	the	oral	cavity	to	atherosclerotic	
plaques	where	it		is	capable	of	citrullinating	proteins	and	generating	ACPA	and	
is	 considered	 one	 the	 predisposing	 factors	 for	 developing	 RA.34	 The	







Plasma	 sGPVI,	 a	 specific	 marker	 of	 platelet	 activation	 is	 increased	 among	
patients	 with	 seropositive	 RA,	 providing	 in	 vivo	 evidence	 that	 the	 GPVI	
pathway	 is	 involved	 in	 antibody-mediated	 platelet	 activation	 in	 humans.	
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I	 have	 shown	 that	 a	 polymorphism	 of	 the	 CX3CR1	 gene,	which	 has	 been	
shown	to	have	a	protective	association	against	atherosclerosis,	has	a	similar	
protective	 association	 against	 RA.	 I	 have	 also	 illustrated	 by	 means	 of	
immunohistochemistry	that	monocytes	co-localise	with	CX3CR1	in	human	
RA	synovium,	providing	further	evidence	of	the	chemotactic	effects	between	
monocytes	 and	 the	 FKN/CX3CR1	 axis.	 Finally	 I	 have	 demonstrated	 an	
association	between	seropositive	RA	and	sGPVI,	a	specific	marker	of	platelet	
activation,	providing	further	evidence	that	platelet	activation	is	associated	
with	seropositive	RA	and	is	likely	antibody	mediated.	
	
	
	
	
	
	
	
	
	
